The Antiangiogenic Therapy in Ovarian Cancer

Loizzi Vera*¹, Cicinelli Ettore¹, Del Vecchio Vittoria¹, Naglieri Emanuele², Girolamo Ranieri³ and Gennaro Cormio ^1,2

Received: May 21, 2018;   Published: May 29, 2018

DOI: 10.26717/BJSTR.2018.04.001121

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

The standard treatment for epithelial ovarian cancer (EOC) consists of optimal cytoreductive surgery followed by platinum-based chemotherapy [1-2]. Bevacizumab has been approved for the treatment of several tumors such as colorectal cancer, non-squamous non-small cell lung cancer, renal cell carcinoma, epithelial ovarian, fallopian tube, and primary peritoneal cancers. The use of antiangiogenic agent in EOC is based on the results of randomized clinical trials which revealed an improved survival rates with the addition of bevacizumab to standard first-line chemotherapeutic drugs [3- 4].

Keywords: Angiogenesis, Vegf, Ovarian Cancer

Mini Review| References|